PL3846788T3 - Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona - Google Patents

Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona

Info

Publication number
PL3846788T3
PL3846788T3 PL19783154.8T PL19783154T PL3846788T3 PL 3846788 T3 PL3846788 T3 PL 3846788T3 PL 19783154 T PL19783154 T PL 19783154T PL 3846788 T3 PL3846788 T3 PL 3846788T3
Authority
PL
Poland
Prior art keywords
parkinson
disease
treatment
pde11 inhibitors
pde11
Prior art date
Application number
PL19783154.8T
Other languages
English (en)
Inventor
Marten Piet Smidt
Lars Philip VAN DER HEIDE
Original Assignee
Universiteit Van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Van Amsterdam filed Critical Universiteit Van Amsterdam
Publication of PL3846788T3 publication Critical patent/PL3846788T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL19783154.8T 2018-09-05 2019-09-05 Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona PL3846788T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18192799 2018-09-05
PCT/NL2019/050578 WO2020050722A1 (en) 2018-09-05 2019-09-05 Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PL3846788T3 true PL3846788T3 (pl) 2026-02-23

Family

ID=63517803

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19783154.8T PL3846788T3 (pl) 2018-09-05 2019-09-05 Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona

Country Status (9)

Country Link
US (1) US20210330736A1 (pl)
EP (1) EP3846788B1 (pl)
JP (2) JP2021535180A (pl)
CN (1) CN112996492A (pl)
DK (1) DK3846788T3 (pl)
ES (1) ES3058213T3 (pl)
FI (1) FI3846788T3 (pl)
PL (1) PL3846788T3 (pl)
WO (1) WO2020050722A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116173035A (zh) * 2021-11-26 2023-05-30 中国科学院深圳先进技术研究院 双嘧达莫在抑制Mcl-1中的应用
WO2025075499A1 (en) * 2023-10-02 2025-04-10 Universiteit Van Amsterdam Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0967284A1 (en) * 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
AU2001255849B8 (en) * 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
FR2846653B1 (fr) * 2002-10-30 2007-04-20 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
WO2007142929A2 (en) * 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
EP2282779B1 (en) * 2008-04-29 2013-03-13 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
WO2013082275A1 (en) * 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
EA034689B1 (ru) * 2012-04-27 2020-03-06 Милленниум Фармасьютикалз, Инк. Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии
JP2013241354A (ja) * 2012-05-18 2013-12-05 Oriza Yuka Kk ホスホジエステラーゼ2阻害剤
US9849132B2 (en) * 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
WO2016145614A1 (en) * 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors

Also Published As

Publication number Publication date
DK3846788T3 (da) 2026-01-12
EP3846788B1 (en) 2025-10-29
EP3846788A1 (en) 2021-07-14
FI3846788T3 (fi) 2025-12-17
JP2024138492A (ja) 2024-10-08
WO2020050722A1 (en) 2020-03-12
US20210330736A1 (en) 2021-10-28
CN112996492A (zh) 2021-06-18
ES3058213T3 (en) 2026-03-09
JP2021535180A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
IL279260A (en) KDM1A inhibitors for the treatment of diseases
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
HRP20251604T1 (hr) Antagonist gremlina‑1 za upotrebu u liječenju raka
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
IL287745A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
PL3846788T3 (pl) Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona
IL275132A (en) C5AR inhibitors for use in the treatment of iatrogenic pain caused by chemotherapy
PL3458045T3 (pl) Ebselen do zastosowania w leczeniu choroby meniere’a
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IT201600122310A1 (it) Composizione per uso nella terapia di alterazioni dell'intestino
PT3448430T (pt) Uso de inibidores da acetilcolinesterase e idalopirdina para reduzir quedas em doentes com doença de parkinson
ITUA20163037A1 (it) Formulazioni per uso nel trattamento o prevenzione di disturbi urologici
IL276697A (en) 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders
DK3423081T3 (da) Sammensætninger til brug i behandlingen af neurologisk sygdom